225 related articles for article (PubMed ID: 23407049)
1. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
3. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
5. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of capecitabine in advanced breast cancer patients.
Largillier R; Etienne-Grimaldi MC; Formento JL; Ciccolini J; Nebbia JF; Ginot A; Francoual M; Renée N; Ferrero JM; Foa C; Namer M; Lacarelle B; Milano G
Clin Cancer Res; 2006 Sep; 12(18):5496-502. PubMed ID: 17000685
[TBL] [Abstract][Full Text] [Related]
7. Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.
van Huis-Tanja LH; Ewing E; van der Straaten RJ; Swen JJ; Baak-Pablo RF; Punt CJ; Gelderblom AJ; Guchelaar HJ
Pharmacogenet Genomics; 2015 Jun; 25(6):279-88. PubMed ID: 25815774
[TBL] [Abstract][Full Text] [Related]
8. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Marcuello E; Altés A; Menoyo A; Rio ED; Baiget M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):835-40. PubMed ID: 16187112
[TBL] [Abstract][Full Text] [Related]
9. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
Afzal S; Gusella M; Vainer B; Vogel UB; Andersen JT; Broedbaek K; Petersen M; Jimenez-Solem E; Bertolaso L; Barile C; Padrini R; Pasini F; Jensen SA; Poulsen HE
Clin Cancer Res; 2011 Jun; 17(11):3822-9. PubMed ID: 21471424
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
12. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
Gonzalez-Haba E; García MI; Cortejoso L; López-Lillo C; Barrueco N; García-Alfonso P; Alvarez S; Jiménez JL; Martín ML; Muñóz-Fernández MA; Sanjurjo M; López-Fernández LA
Pharmacogenomics; 2010 Dec; 11(12):1715-23. PubMed ID: 21142915
[TBL] [Abstract][Full Text] [Related]
14. Evolution of capecitabine dosing in colorectal cancer.
Sun W
Clin Colorectal Cancer; 2010 Jan; 9(1):31-9. PubMed ID: 20100686
[TBL] [Abstract][Full Text] [Related]
15. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
[TBL] [Abstract][Full Text] [Related]
17. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
Etienne MC; Formento JL; Chazal M; Francoual M; Magné N; Formento P; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
Pharmacogenetics; 2004 Dec; 14(12):785-92. PubMed ID: 15608557
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
19. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Wang Y; Yang H; Wei JF; Meng L
Curr Med Res Opin; 2012 Dec; 28(12):1911-9. PubMed ID: 23145857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
